

Attorney Docket No. 9151-6

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Wheeler et al.

Serial No.: 09/823,069

Filed: March 30, 2001

For: METHODS AND COMPOSITIONS UTILIZING AN
ALTERNATIVE SPLICE VARIANT OF THE SIGMA-1 RECEPTOR

Date: July 18, 2001

Assistant Commissioner for Patents
Washington, DC 20231

**AMENDMENT AND STATEMENT IN SUPPORT OF FILING A
SEQUENCE LISTING UNDER 37 CFR § 1.821(f)**

Sir:

Please reconsider the above-captioned application in view of the following amendments and remarks.

AMENDMENT

Please insert supplemental pages 1 through 5, enclosed herewith, after the claims of the present application. The supplemental pages comprise the Sequence Listing for the application.

REMARKS AND STATEMENT

A Notice to File Missing Parts Of Non-Provisional Application has been issued in the present case, and Applicants have been instructed to comply with the requirements for patent applications containing nucleotide sequences and/or amino acid sequences. In response to the Notice, Applicants hereby submit a paper copy of a Sequence Listing in the form of supplemental pages numbered 1 through 5, which should be inserted into the present application after the claims.

The supplemental pages submitted herewith contain the Sequence Listing required by 37 C.F.R. § 1.821(c) for nucleotide and peptide sequences described in the specification, and are submitted as substitute (supplemental) sheets as required by 37 C.F.R. § 1.825(a). The sequences are also provided on computer diskette in a computer readable form as required by 37 C.F.R. §§ 1.821(e) and 1.824.

09/823,069-5

In re: Wheeler et al.
Serial No.: 09/823,069
Filed: March 30, 2001
Page 2

I hereby state as required by 37 C.F.R. § 1.821(f) that the content of the paper copy of the Sequence Listing and the computer readable copy are the same.

I also hereby state as required by 37 C.F.R. §1.825(a) that the substitute sheets contain no new matter.


Respectfully submitted,


Sorojini J. Biswas
Registration No. 39,111

CUSTOMER NUMBER 20792
Myers Bigel Sibley & Sajovec
PO Box 37428
Raleigh NC 27627
Tel (919) 854-1400
Fax (919) 854-1401

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, Washington, DC 20231, on July 18, 2001.


Meredith Schuessler
Date of Signature: July 18, 2001

09/823,069
07/2001
100220



SEQUENCE LISTING

<110> Mach, Robert
Childers, Steven
Shelness, Gregory
Wang, Li-Ming

<120> METHODS AND COMPOSITIONS UTILIZING AN ALTERNATIVE SPLICE VARIANT OF THE SIGMA-1 RECEPTOR

<130> 9151.6

<140> 09/823,069

<141> 2001-03-30

<150> US 60/193,694

<151> 2000-03-31

<160> 6

<170> PatentIn version 3.0

<210> 1

<211> 579

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(579)

<400> 1

atg cag tgg gcc gtg ggc cgg cgg tgg gcg tgg gcc gcg ctg ctc ctg 48
Met Gln Trp Ala Val Gly Arg Arg Trp Ala Trp Ala Ala Leu Leu Leu
1 5 10 15

gct gtc gca gcg gtg ctg acc cag gtc gtc tgg ctc tgg ctg ggt acg 96
Ala Val Ala Ala Val Leu Thr Gln Val Val Trp Leu Trp Leu Gly Thr
20 25 30

cag agc ttc gtc ttc cag cgc gaa gag ata gcg cag ttg gcg cgg cag 144
Gln Ser Phe Val Phe Gln Arg Glu Glu Ile Ala Gln Leu Ala Arg Gln
35 40 45

tac gct ggg ctg gac cac gag ctg gcc ttc tct cgt ctg atc gtg gag 192
Tyr Ala Gly Leu Asp His Glu Leu Ala Phe Ser Arg Leu Ile Val Glu
50 55 60

ctg cgg cgg ctg cac cca ggc cac gtg ctg ccc gac gag gag ctg cag 240
Leu Arg Arg Leu His Pro Gly His Val Leu Pro Asp Glu Glu Leu Gln
65 70 75 80

tgg gtg ttc gtg aat gcg ggt ggc tgg atg ggc gcc atg tgc ctt ctg 288
Trp Val Phe Val Asn Ala Gly Gly Trp Met Gly Ala Met Cys Leu Leu
85 90 95

09823069-02001

cac gcc tcg ctg tcc gag tat gtg ctg ctc ttc ggc acc gcc ttg ggc 336
His Ala Ser Leu Ser Glu Tyr Val Leu Leu Phe Gly Thr Ala Leu Gly
100 105 110

tcc cgc ggc cac tcg ggg gag acg gta gta cac ggg cct ggt gag gca 384
Ser Arg Gly His Ser Gly Glu Thr Val Val His Gly Pro Gly Glu Ala
115 120 125

aca gct gtg gag tgg ggg cca aac aca tgg atg gtg gag tac ggc cgg 432
Thr Ala Val Glu Trp Gly Pro Asn Thr Trp Met Val Glu Tyr Gly Arg
130 135 140

ggc gtc atc cca tcc acc ctg gcc ttc gcg ctg gcc gac act gtc ttc 480
Gly Val Ile Pro Ser Thr Leu Ala Phe Ala Leu Ala Asp Thr Val Phe
145 150 155 160

agc acc cag gac ttc ctc acc ctc ttc tat act ctt cgc tcc tat gct 528
Ser Thr Gln Asp Phe Leu Thr Leu Phe Tyr Thr Leu Arg Ser Tyr Ala
165 170 175

cgg ggc ctc cgg ctt gag ctc acc acc tac ctc ttt ggc cag gac cct 576
Arg Gly Leu Arg Leu Glu Leu Thr Thr Tyr Leu Phe Gly Gln Asp Pro
180 185 190

tga 579

<210> 2
<211> 192
<212> PRT
<213> Homo sapiens

<400> 2

Met Gln Trp Ala Val Gly Arg Arg Trp Ala Trp Ala Ala Leu Leu Leu
1 5 10 15

Ala Val Ala Ala Val Leu Thr Gln Val Val Trp Leu Trp Leu Gly Thr
20 25 30

Gln Ser Phe Val Phe Gln Arg Glu Glu Ile Ala Gln Leu Ala Arg Gln
35 40 45

Tyr Ala Gly Leu Asp His Glu Leu Ala Phe Ser Arg Leu Ile Val Glu
50 55 60

Leu Arg Arg Leu His Pro Gly His Val Leu Pro Asp Glu Glu Leu Gln
65 70 75 80

Trp Val Phe Val Asn Ala Gly Gly Trp Met Gly Ala Met Cys Leu Leu
85 90 95

His Ala Ser Leu Ser Glu Tyr Val Leu Leu Phe Gly Thr Ala Leu Gly
 100 105 110

Ser Arg Gly His Ser Gly Glu Thr Val Val His Gly Pro Gly Glu Ala
 115 120 125

Thr Ala Val Glu Trp Gly Pro Asn Thr Trp Met Val Glu Tyr Gly Arg
 130 135 140

Gly Val Ile Pro Ser Thr Leu Ala Phe Ala Leu Ala Asp Thr Val Phe
 145 150 155 160

Ser Thr Gln Asp Phe Leu Thr Leu Phe Tyr Thr Leu Arg Ser Tyr Ala
 165 170 175

Arg Gly Leu Arg Leu Glu Leu Thr Thr Tyr Leu Phe Gly Gln Asp Pro
 180 185 190

<210> 3
 <211> 579
 <212> DNA
 <213> Mus musculus

<220>
 <221> CDS
 <222> (1)..(579)

<400> 3
 atg ccg tgg gcc gcg gga cgg cgg tgg gca tgg atc acc ctg att ctg 48
 Met Pro Trp Ala Ala Gly Arg Arg Trp Ala Trp Ile Thr Leu Ile Leu
 1 5 10 15
 act att atc gca gtg ctg atc cag gcc gcc tgg ttg tgg ctg ggc act 96
 Thr Ile Ile Ala Val Leu Ile Gln Ala Ala Trp Leu Trp Leu Gly Thr
 20 25 30
 caa aac ttc gtc ttc tct aga gaa gaa ata gcg cag ctt gct cga cag 144
 Gln Asn Phe Val Phe Ser Arg Glu Glu Ile Ala Gln Leu Ala Arg Gln
 35 40 45
 tat gcg ggg ctg gac cat gag ctt gcc ttc tct cgg ctg atc gtg gag 192
 Tyr Ala Gly Leu Asp His Glu Leu Ala Phe Ser Arg Leu Ile Val Glu
 50 55 60
 ctg cgg agg ctg cac cca ggc cac gtg ctg ccg gat gag gag ctg cag 240
 Leu Arg Arg Leu His Pro Gly His Val Leu Pro Asp Glu Glu Leu Gln
 65 70 75 80
 tgg gta ttt gtg aac gcg ggc ggc tgg atg ggc gcc atg tgt att ctg 288
 Trp Val Phe Val Asn Ala Gly Gly Trp Met Gly Ala Met Cys Ile Leu

	85						90						95						
cac gcc tgc ctg tct gag tac gtg	ctg ctc ttc ggc acc gcc ctg ggc	336																	
His Ala Ser Leu Ser Glu Tyr Val	Leu Leu Phe Gly Thr Ala Leu Gly																		
	100 105 110																		
tcc cat ggc cat tcg gga gag aca gtt gta cac ggg cct gga gaa gca	384																		
Ser His Gly His Ser Gly Glu Thr Val Val His Gly Pro Gly Glu Ala																			
	115 120 125																		
acg get ctg gag tgg gga cca aac acg tgg atg gtg gag tac ggc cgg	432																		
Thr Ala Leu Glu Trp Gly Pro Asn Thr Trp Met Val Glu Tyr Gly Arg																			
	130 135 140																		
ggt gtt att ccg tct acc ctg ttc ttt gca cta gcc gac acc ttc ttc	480																		
Gly Val Ile Pro Ser Thr Leu Phe Phe Ala Leu Ala Asp Thr Phe Phe																			
	145 150 155 160																		
ggc acc cag gac tac ctc aca ctc ttc tat acc ctt cgg gcc tat gcc	528																		
Gly Thr Gln Asp Tyr Leu Thr Leu Phe Tyr Thr Leu Arg Ala Tyr Ala																			
	165 170 175																		
cgg ggc ctc cgg ctt gag ctt acc acc tac ctc ttt ggc caa gac tcc	576																		
Arg Gly Leu Arg Leu Glu Leu Thr Thr Tyr Leu Phe Gly Gln Asp Ser																			
	180 185 190																		
tga	579																		
<210>	4																		
<211>	192																		
<212>	PRT																		
<213>	Mus musculus																		
<400>	4																		
Met Pro Trp Ala Ala Gly Arg Arg Trp Ala Trp Ile Thr Leu Ile Leu																			
1	5 10 15																		
Thr Ile Ile Ala Val Leu Ile Gln Ala Ala Trp Leu Trp Leu Gly Thr																			
	20 25 30																		
Gln Asn Phe Val Phe Ser Arg Glu Glu Ile Ala Gln Leu Ala Arg Gln																			
	35 40 45																		
Tyr Ala Gly Leu Asp His Glu Leu Ala Phe Ser Arg Leu Ile Val Glu																			
	50 55 60																		
Leu Arg Arg Leu His Pro Gly His Val Leu Pro Asp Glu Glu Leu Gln																			
65	70 75 80																		
Trp Val Phe Val Asn Ala Gly Gly Trp Met Gly Ala Met Cys Ile Leu																			

85

90

95

His Ala Ser Leu Ser Glu Tyr Val Leu Leu Phe Gly Thr Ala Leu Gly
 100 105 110

Ser His Gly His Ser Gly Glu Thr Val Val His Gly Pro Gly Glu Ala
 115 120 125

Thr Ala Leu Glu Trp Gly Pro Asn Thr Trp Met Val Glu Tyr Gly Arg
 130 135 140

Gly Val Ile Pro Ser Thr Leu Phe Phe Ala Leu Ala Asp Thr Phe Phe
 145 150 155 160

Gly Thr Gln Asp Tyr Leu Thr Leu Phe Tyr Thr Leu Arg Ala Tyr Ala
 165 170 175

Arg Gly Leu Arg Leu Glu Leu Thr Thr Tyr Leu Phe Gly Gln Asp Ser
 180 185 190

<210> 5
 <211> 31
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> misc_feature
 <222> (1)..(31)
 <223> Synthetic Oligonucleotide Primer.

<400> 5
 gaacgaattc agaagtcctg gggccgcggg a

31

<210> 6
 <211> 31
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> misc_feature
 <222> (1)..(31)
 <223> Synthetic Oligonucleotide Primer.

<400> 6
 taacggtacc tcaggagtct tggccaaaga g

31